- Home
- SYT vs CODX Comparison
SYT vs CODX Comparison
Compare SYT & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYT
- CODX
- Stock Information
- Founded
- SYT 2010
- CODX 2013
- Country
- SYT Japan
- CODX United States
- Employees
- SYT N/A
- CODX N/A
- Industry
- SYT Real Estate
- CODX Medical/Dental Instruments
- Sector
- SYT Finance
- CODX Health Care
- Exchange
- SYT Nasdaq
- CODX Nasdaq
- Market Cap
- SYT 40.2M
- CODX 39.3M
- IPO Year
- SYT 2023
- CODX 2017
- Fundamental
- Price
- SYT $1.61
- CODX $1.06
- Analyst Decision
- SYT
- CODX Hold
- Analyst Count
- SYT 0
- CODX 1
- Target Price
- SYT N/A
- CODX $1.50
- AVG Volume (30 Days)
- SYT 7.0K
- CODX 77.0K
- Earning Date
- SYT 09-27-2024
- CODX 11-07-2024
- Dividend Yield
- SYT 0.43%
- CODX N/A
- EPS Growth
- SYT N/A
- CODX N/A
- EPS
- SYT 0.08
- CODX N/A
- Revenue
- SYT $149,124,408.00
- CODX $7,321,012.00
- Revenue This Year
- SYT N/A
- CODX N/A
- Revenue Next Year
- SYT N/A
- CODX N/A
- P/E Ratio
- SYT $20.31
- CODX N/A
- Revenue Growth
- SYT 3.11
- CODX 57.16
- 52 Week Low
- SYT $1.43
- CODX $1.00
- 52 Week High
- SYT $8.74
- CODX $2.23
- Technical
- Relative Strength Index (RSI)
- SYT 48.93
- CODX 30.68
- Support Level
- SYT $1.58
- CODX $1.11
- Resistance Level
- SYT $1.67
- CODX $1.19
- Average True Range (ATR)
- SYT 0.07
- CODX 0.05
- MACD
- SYT 0.02
- CODX -0.01
- Stochastic Oscillator
- SYT 46.67
- CODX 5.11
About SYT SYLA Technologies Co. Ltd.
SYLA Technologies Co Ltd is a property technology company. It provides asset management platform systems that facilitate real estate crowd-funding as well as the purchase and sale of real estate.
About CODX Co-Diagnostics Inc.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.